Pfizer Inc. (FRA:PFE)
21.19
+0.34 (1.61%)
Oct 20, 2025, 9:55 PM CET
Pfizer Employees
Pfizer had 81,000 employees as of December 31, 2024. The number of employees decreased by 7,000 or -7.95% compared to the previous year.
Employees
81,000
Change (1Y)
-7,000
Growth (1Y)
-7.95%
Revenue / Employee
€672,611
Profits / Employee
€113,294
Market Cap
119.48B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 81,000 | -7,000 | -7.95% |
Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
Dec 31, 2021 | 79,000 | 500 | 0.64% |
Dec 31, 2020 | 78,500 | -9,800 | -11.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Bayer Aktiengesellschaft | 91,864 |
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Fielmann Group AG | 24,363 |
Sartorius Aktiengesellschaft | 13,528 |
Carl Zeiss Meditec AG | 5,730 |
Pfizer News
- 15 hours ago - Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus
- 16 hours ago - Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Cancer Treatment - GuruFocus
- 19 hours ago - Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy - GlobeNewsWire
- 1 day ago - Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
- 1 day ago - Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
- 1 day ago - XTANDI Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Wallstreet:Online
- 1 day ago - XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Business Wire
- 1 day ago - Pfizer’s BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Wallstreet:Online